Zydus Lifesciences Ltd. Q3 FY2025 results: revenue ₹5,269 crore, up 17.0% on the year
Zydus Lifesciences Ltd. (ZYDUSLIFE) reported consolidated revenue from operations of ₹5,269 crore for Q3 FY2025, the quarter ended 31 December 2024, up 17.0% on the same quarter a year earlier. Profit after tax was ₹1,026 crore, up 29.9% on the year, and earnings per share ₹10.17. The figures are the company's own, from the unaudited results it filed with NSE on 5 February 2025.
The quarter, against the one before and a year earlier
| Line | Q3 FY2025 | Q2 FY2025 | Q3 FY2024 | Change on the year |
|---|---|---|---|---|
| Revenue from operations | 5,269 | 5,237 | 4,505 | +17.0% |
| Other income | 58 | 68 | 38 | +52.5% |
| Total income | 5,327 | 5,305 | 4,543 | +17.3% |
| Cost of materials consumed | 1,026 | 1,066 | 1,063 | -3.5% |
| Purchases of stock-in-trade | 571 | 484 | 459 | +24.3% |
| Changes in inventories | -14 | -79 | -54 | n/a |
| Employee benefit expense | 946 | 879 | 817 | +15.8% |
| Finance costs | 32 | 25 | 20 | +61.6% |
| Depreciation, depletion and amortisation | 229 | 234 | 195 | +17.6% |
| Other expenses | 1,352 | 1,425 | 1,117 | +21.0% |
| Total expenses | 4,142 | 4,034 | 3,617 | +14.5% |
| Profit before exceptional items and tax | 1,184 | 1,271 | 926 | +27.9% |
| Exceptional items | 0 | 0 | 0 | n/a |
| Profit before tax | 1,184 | 1,271 | 926 | +27.9% |
| Current tax | 39 | 366 | 150 | -73.7% |
| Deferred tax | 140 | 8 | 64 | +118.7% |
| Total tax | 180 | 373 | 214 | -16.0% |
| Profit after tax | 1,026 | 920 | 790 | +29.9% |
| Attributable to owners of the parent | 1,024 | 911 | 790 | +29.6% |
| Other comprehensive income | -43 | -10 | 20 | n/a |
| Total comprehensive income | 983 | 910 | 810 | +21.3% |
| EPS, basic | ₹10.17 | ₹9.06 | ₹7.80 | +30.4% |
| EPS, diluted | ₹10.17 | ₹9.06 | ₹7.80 | +30.4% |
₹ crore except per share.
Quarterly results, the last 12 quarters
| Q2 FY2024 | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Q4 FY2026 | Q1 FY2027 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,369 | 4,505 | 5,534 | 6,208 | 5,237 | 5,269 | 6,528 | 6,574 | 6,123 | 6,864 | 7,587 | 8,017 |
| Expenses | 3,416 | 3,617 | 4,143 | 4,371 | 4,034 | 4,142 | 4,717 | 4,808 | 4,511 | 5,538 | 5,664 | 6,798 |
| Operating profit | 1,146 | 1,102 | 1,631 | 2,084 | 1,461 | 1,388 | 2,126 | 2,088 | 2,016 | 1,816 | 2,554 | 1,929 |
| OPM % | 26% | 24% | 29% | 34% | 28% | 26% | 33% | 32% | 33% | 26% | 34% | 24% |
| Other income | 54 | 38 | 156 | 63 | 68 | 58 | 81 | 155 | 109 | 111 | 134 | 106 |
| Interest | 9 | 20 | 35 | 32 | 25 | 32 | 77 | 85 | 101 | 130 | 123 | 156 |
| Depreciation | 184 | 195 | 205 | 215 | 234 | 229 | 238 | 238 | 302 | 360 | 508 | 555 |
| Exceptional items | 0 | 0 | 0 | 0 | 0 | 0 | -220 | 0 | -34 | -85 | -398 | -18 |
| Profit before tax | 1,007 | 926 | 1,547 | 1,900 | 1,271 | 1,184 | 1,672 | 1,921 | 1,687 | 1,353 | 1,660 | 1,307 |
| Tax % | 22% | 23% | 21% | 23% | 29% | 15% | 25% | 23% | 27% | 29% | 19% | 27% |
| Net profit | 803 | 790 | 1,246 | 1,482 | 920 | 1,026 | 1,244 | 1,521 | 1,239 | 1,023 | 1,341 | 990 |
| EPS in ₹ | ₹7.91 | ₹7.80 | ₹11.69 | ₹14.11 | ₹9.06 | ₹10.17 | ₹11.64 | ₹14.58 | ₹12.51 | ₹10.36 | ₹12.65 | ₹9.35 |
| Filing | NSE | NSE | NSE | NSE | NSE | NSE | Filing | Filing | Filing | Filing | Filing | Filing |
₹ crore except per share, consolidated, as filed with the exchange. Operating profit is sales less the expenses other than interest and depreciation, OPM is that over sales, and tax % is tax over profit before tax: arithmetic on the filed lines; everything else is as filed. Quarters before December 2024 are from the exchange's earlier results feed, which carries the filed lines without the filing itself; the column links to the exchange's page for the company.
Source
Unaudited consolidated results for the quarter ended 31 December 2024, filed with NSE on 5 February 2025: the result statement. All of Zydus Lifesciences Ltd.'s results: NSE company page.
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.